Valuation of biomarkers

Nature Reviews Drug Discovery

Volumn 10, Issue 4, 2011, Pages 253-254

  Hurko, Orest ^a   Jones, Graham K ^b  

^a Biologics Consulting Group   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; COST CONTROL; DISEASE ACTIVITY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG PROGRAM; DRUG TARGETING; ECONOMIC ASPECT; GOVERNMENT REGULATION; HEART INFARCTION; INVESTMENT; KIDNEY FAILURE; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTRATION; RISK MANAGEMENT; STROKE; TOXICITY TESTING;

BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; ENDPOINT DETERMINATION; HUMANS; MODELS, THEORETICAL;

EID: 79953300310     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3417     Document Type: Article

References (6)

1. Peck, R. W. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discov. Today 12, 289-294 (2007). (Pubitemid 46486663)
2. Hurko, O. The uses of biomarkers in drug development. Ann. NY Acad. Sci. 180, 1-10 (2009).
3. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203-214 (2010).
4. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003). (Pubitemid 36279392)
5. Fleming, T. R. & DeMets, D. L. Surrogate end points in clinical trials: are we being misled? Ann. Int. Med. 125, 605-613 (1996). (Pubitemid 126450094)
6. Prentice, R. L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8, 431-440 (1989). (Pubitemid 19105891)